Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1a1*28 polymorphism carriers

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2236-2242

  Ferraris, Laurenzia ^a   Viganö, Ottavia ^a   Peri, Anna ^a   Tarkowski, Maciej ^a   Milani, Greta ^a   Bonora, Stefano ^b   Adorni, Fulvio ^c   Gervasoni, Cristina ^a   Clementi, Emilio ^a,d   Di perri, Giovanni ^b   Galli, Massimo ^a   Riva, Agostino ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CNR   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Antiretroviral therapy; HIV; Hyperbilirubinaemia; Pharmacogenetics; Therapeutic drug monitoring

Indexed keywords

ATAZANAVIR; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD; WILD TYPE;

ADULT; ANTI-HIV AGENTS; BILIRUBIN; FEMALE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84865387874     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks175     Document Type: Article

References (32)

1. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 2008; 21: 16-24.
2. Burchell B, Brierley C, Rance D. Specificity of human UDPglucuronosyl-transferases and xenobiotic glucuronidation. Life Sci 1995; 57: 1819-31.
3. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDPglucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 59: 405-14.
4. Bosma PJ, Seppen J, Goldhoorn B et al. Bilirubin UDPglucuronosyltransferase is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269: 17960-4.
5. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyl-transferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-4.
6. Mackenzie P, Owens I, Burchell B et al. The UDP glycosyl-transferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-69.
7. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-5.
8. Monaghan G, Ryan M, Seddon R et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-81.
9. Zucker SD, Qin X, Rouster SD et al. Mechanism of indinavir induced hyperbilirubinemia. Proc Acad Natl Acad Sci USA 2001; 98: 12671-6.
10. O'Mara E, Randall D, Passarell J et al. Population pharmacodynamic assessment of atazanavir exposure, UGT1A1 genotype and safety in healthy human subjects. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1253. American Society for Microbiology, Washington, DC, USA.
11. Ghosn J, Carosi G, Moreno S et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010; 15: 993-1002.
12. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-7.
13. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
14. Bristol-Myers Squib Company. Reyataz (Atazanavir Sulfate) Product Information Guide 2003. Princeton, NJ, USA: Bristol-Myers Squib Company.
15. Mann M, Piazza-Hepp T, Koller E et al. Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the Food and Drug Administration. AIDS Patient Care STDs 1999; 13: 287-95.
16. Rubio R, Serrano O, Carmena J et al. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Med 2010; 11: 545-53.
17. Vora S, Marcelin AG, Gunthard HF et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitorexperienced patients. AIDS 2006; 20: 35-40.
18. Squires KE, Young B, Dejesus E et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/ lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010; 24: 2019-27.
19. Carey D, Amin J, Boyd M et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1878-88.
20. Giuntini R, Martinelli C, Ricci E et al. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11: 40-5.
21. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6.
22. Kaul S, Bassi K, Carr A et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-1616. American Society for Microbiology, Washington, DC, USA.
23. Von Hentig N, Dauer B, Haberl A et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV 1-infected adults. Eur J Clin Pharmacol 2007; 63: 935-40.
24. Pellegrin I, Breilh D, Ragnaud JM et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters. Antivir Ther 2006; 11: 421-9.
25. Stoehr W, Back D, Dunn D et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother 2010; 65: 129-37.
26. Rotger M, Taffe P, Bleiber G et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192: 1381-6.
27. Lankisch TO, Moebius U, Wehmeier M et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44: 1324-32.
28. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21: 41-6.
29. Rodriguez-Novoa S, Barreiro P, Rendon A et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C-T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42: 291-5.
30. Siccardi M, D'Avolio A, Baietto L et al. Association of a single nucleotide polymorphism in the pregnane X receptor with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47: 1222-5.
31. Hartkoorn RC, Kwan WS, Shallcross V et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20: 112-20.
32. Strassburg CP, Manns MP. Jaundice, genes and promoters. J Hepatol 2000; 33: 476-9.